The macrolides

Bibliography

• WHITMAN MS, TUNKEL AR:
   Google Scholar
• Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect. Cont. Hosp. Epiderniol. (1992) 13(6):357–368.
   PubMed Web of Science ®Google Scholar
• ZUCKERMAN JM, KAYE KM: The newer macrolides - azithromycin and clarithromycin. Infect. Dis. Chi]. N Am. (1995) 9:731–745.
   PubMed Web of Science ®Google Scholar
• AMSDEN GW: Erythromycin, clarithromycin and azithromycin: are the differences real? Chi]. Therapeu. (1996) 18(1):56–72.
   Google Scholar
• McKENNA S, EVANS GA, THE CANADIAN INFECTIOUS DISEASE SOCIETY ANTMICROBIAL AGENTS
   Google Scholar
• COMMITTEE: Macrolides: a Canadian Infectious Disease Society position paper. Can J. Infect. Dis. (2001) 12(4):218–231.
   PubMedGoogle Scholar
• BLONDEAU JM, TILLOTSON GS: A critical review of the changing etiology of community-acquired pneumonia and the clinical impact of antimicrobial resistance. Chest (2000) 118(Suppl.):S235.
   Google Scholar
• KIRST HA, SIDES GD: New directions for macrolide antibiotics: structure modifications and in vitro activity. Antimicrob. Agents Chemother. (1989) 33:1413–1418.
   PubMed Web of Science ®Google Scholar
• DREW RH, GALLIS HA: Azithromycin - spectrum of activity, pharmacokinetics and clinical applications. Pharmacotherapy (1992) 12(3):161–173.
   PubMed Web of Science ®Google Scholar
• FIESE EF, STEFFEN SH: Comparison of the acid stability of azithromycin and erythromycin A. j Antimicrob. Chemother (1990) 25(Suppl.A):39–47.
   Google Scholar
• PERITI E MAZZIE T, MINI E, NOVELLI A: Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states. I CM]. Pharmacokinet. (1989) 16:193–214.
   Google Scholar
• RETSEMA JA, GIRARD AE, GIRARD D, MILISEN WB: Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo. Antimicrob. Chemother. (1990) 25(Suppl. A):83–89.
   Google Scholar
• PISCITELLI SC, DANZIGER LH, RODVOLD KA: Clarithromycin and azithromycin: new macrolide antibiotics. CM]. Pharm. (1992) 11:137–152.
   Google Scholar
• BRISSON-NOEL A, TRIEU-CUOT E COURVALIN P: Mechanism of action of spiramycin and other macrolides.
   Google Scholar
• Antimicrob. Chemother. (1988) 22(Suppl. B):13–23.
   Google Scholar
• WEISBLUM B: Inducible resistance to macrolides, lincosamides, and streptogramin type B antibiotics: the resistance phenotype, its biological diversity and structural elements that regulate expression - a review. Antimicrob. Chemother. (1985) 16(Suppl. A):63–90.
   Google Scholar
• MENNINGER JR: Functional consequences of binding macrolides to ribosomes. Antimicrob. Chemother. (1985) 16(Suppl. A):23–34.
   Google Scholar
• RETSEMA JA, GIRARD A, SCHELKY W et al: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob. Agents Chemother. (1987) 31:1939–1947.
   PubMed Web of Science ®Google Scholar
• FERNANDES PB, HARDY DJ: Comparative in vitro potencies of nine new macrolides. Drugs Exp. Clin. Res. (1988) 14:445–451.
   PubMedGoogle Scholar
• EISENBERG E, BARZA M: Azithromycin and clarithromycin. Cum: Clin. Top. Infect. Dis. (1994) 14:52–79.
   PubMedGoogle Scholar
• EADY EA, ROSS JI, COVE JH: Multiple mechanisms of erythromycin resistance. Antimicrob. Chemother. (1990) 26:461–465.
   Web of Science ®Google Scholar
• AMSDEN GW: Pneumococcal macrolide resistance - myth or reality?I Antimicrob. Chemother. (1999) 44:1–6.
   Web of Science ®Google Scholar
• FOSTER TJ: Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria. Microbial Rev. (1983) 47:361–409.
   PubMedGoogle Scholar
• FERNANDES PB, BAKER WR,
   Google Scholar
• FREIBERG LA etal.: New macrolides active against Streptococcus pyagerres with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrob. Agents Chemother. (1989) 33:78–81.
   PubMed Web of Science ®Google Scholar
• BLONDEAU JM, VAUGHAN D, LASKOWSKI R, BORSOS S, THE CANADIAN ANTIMICROBIAL STUDY GROUP: Susceptibility of Canadian isolates of Haemophilus irilluenzae, Moraxella catarrhalis and Streptococcus prieumarriae to oral antimicrobial agents. Internat. J. Antmicrob. Agents (2001) 117:457–464.
   Web of Science ®Google Scholar
• HOBAN DJ, WIERZBOWSKI AK, NICHOL K, ZHANEL GG: Macrolide-resistant Streptococcus prieumaniae in Canada during 1998–1999: prevalence of met(A) and erm(B) and susceptibilities to ketolides. Antimicrob. Agents Chemother. (2001) 45(7):2147–2150.
   Google Scholar
• CARBON C, POOLE MD: The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. j Chemother. (1999) 11(2):107–118.
   Google Scholar
• BLONDEAU JM, TILLOTSON GS: Antimicrobial susceptibility patterns of respiratory pathogens - a global perspective. Sem. Resp. Infect. (2000) 15:195–207.
   PubMedGoogle Scholar
• SAHM DF, JONES ME, HICKEY ML, DIANKUN DR, MANI SV, THORNSBERRY C: Resistance surveillance of Streptococcus prieumarriae, Haemophilus inlluenzae and Mmaxella catarrhalis isolated in Asia and Europe, 1997-1998.1 Antimicrob. Chemother. (2000) 45:457–466.
   PubMed Web of Science ®Google Scholar
• THORNSBERRY C, OGILVIE P, KAHN J,MAURIZ Y, THE LABORATORY INVESTIGATOR GROUP: Surveillance of antmicrobial resistance in Streptococcus prieumaniae, Haemophilus irilluenzae and Moraxella catarrhalis in the United States ml 996-1997 respiratory season. Diagn. Microbial. Infect. Dis. (1997) 29:249–257.
   PubMed Web of Science ®Google Scholar
• JONES RN, JACOBS MR,
   Google Scholar
• WASHINGTON JA, PFALLER MA: A 1994-94 survey of Haemophilus influenzae susceptibility to ten orally administered agents: a 187 clinical laboratory center sample in the United States. Diagn. Microbial. Infect. Dis. (1997) 27:75–83.
   PubMed Web of Science ®Google Scholar
• FELMINGHAM D, ROBBINS MJ, TESFASLASIE Y, HARDING I, SHRIMPTON S, GRUNEBERG RN: Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. I Antimicrob. Chemother. (1998) 41:411–415.
   PubMed Web of Science ®Google Scholar
• FELMINGHAM D, WASHINGTON J, THE ALEXANDER PROJECT GROUP: Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996.
   Google Scholar
• Chemother. (1999) 11:5–21.
   Google Scholar
• MATHAI D, LEWIS MT, KUGLER KC, PFALLER MA, JONES RN, THE SENTRY PARTICIPANTS GROUP (NORTH AMERICA): Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia - I-results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diag. Microbial. Infect. Dis. (2001) 39:105–116.
   PubMed Web of Science ®Google Scholar
• FELMINGHAM D, GRUNEBERG RN:
   Google Scholar
• Comparative in vitro activity of 16 antimicrobials against 5442 community-acquired, lower respiratory tract pathogens: the Alexander Project, 1997. Proceedings of the 36th IDSA, Denver, USA (1998) 198 (Fr).
   Google Scholar
• DOERN GV, HEILMANN KP HUYNH HK, RHOMBERG PR, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. (2001) 45:1721–1729.
   PubMed Web of Science ®Google Scholar
• SHORTRIGE D, URBAN C, RAHAL JJ, MARIANO N, RAMER N, TANAKA SK: Prevalence of ermAm and melE in penicillin resistant Streptococcus prieumaniae. In: Program and abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, Spain (1998). Abstract 3.13. Wallace Communications Inc., Atlanta, GA.
   Google Scholar
• MARCHESE A, DEBBIA E, PESCE A et al.: Comparative activities of amoxycillin and 10 other oral drugs against penicillin-susceptible and resistant S. prieumarriae strains recently isolated in Italy. Clin. Microbial Infect. (1998) 4:170–173.
   PubMedGoogle Scholar
• TONOLI E, MARCHESE A, DEBBIA EA, SCHITO GC: Prevalence and characterization of the mechanisms of macrolide resistance in 830 penicillin-susceptible S. prieumarriae isolated in Italy during 1993–1997. In: Program and Abstracts of the 4 International Conference on the Macrolides, Azalides and Ketolides, Barcelona, Spain (1998). Abstract 3.17, Wallace Communications, Inc., Atlanta, GA.
   Google Scholar
• FOULDS G, SHEPARD RM, JOHNSON RB: The pharmacokinetics of azithromycin in human serum and tissues. I Antimicrob. Chemother. (1990) 25(Suppl.A):73–82.
   Google Scholar
• NEU HC: The development of macrolides: clarithromycin in perspective. I Antimicrob. Chemother. (1991) 27(Suppl.A):1–9.
   Google Scholar
• HOPKINS S: Clinical toleration and safety of azithromycin. Amer. J. Med. (1991) 91\(Supp1.3A):40S–45S.
   Google Scholar
• GLADUE RP, SNIDER ME: Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. (1990) 34:1056–1060.
   PubMed Web of Science ®Google Scholar
• BERMUDEZ LE, INDERLIED C, YOUNG LS: Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob. Agents Chemother. (1991) 35:2625–2629.
   PubMed Web of Science ®Google Scholar
• GLADUE RP, BRIGHT GM, ISAACSON RE, NEWBORG MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. (1989) 33:277–282.
   PubMed Web of Science ®Google Scholar
• CORNISH P: The new macrolides: azithromycin and clarithromycin. Cilia. Pharmacal (1995) 2(4):153–166.
   Google Scholar
• LALAK NJ, MORRIS DL: Azithromycin clinical pharmacokinetics. Cilia. Pharmacakinet. (1993) 25:370–374.
   PubMed Web of Science ®Google Scholar
• DUNN CJ, BARRADELL LB: Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs (1996) 51(3):483–505.
   PubMed Web of Science ®Google Scholar
• COOPER MA, NYE K, ANDREWS JM et al.: The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. j Antimicrob. Chemother. (1990) 26:533–538.
   PubMed Web of Science ®Google Scholar
• THAKKER KM, CARIDI F, POWELL M, CHUNG M: Multiple dose pharmacokinetics of azithromycin following 1 hour intravenous infusions in hospitalized patients with community-acquired pneumonia (abstract). Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. (1997) 37:24.
   Google Scholar
• LeBEL M: Clinical pharmacokinetics of clarithromycin. Can. j Infect. Dis. (1993) 4 (Suppl.A) :10A–12A.
   Google Scholar
• CHU S, PARK Y, LOCKE C, WILSON DS, CAVANAUGH JC: Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. ..J. Cliii. Pharmacal (1992) 32:32–36.
   PubMed Web of Science ®Google Scholar
• CHU S, DEATON R, CAVANAUGH J: Absolute bioavailabity of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother. (1992) 36:1147–1150.
   PubMed Web of Science ®Google Scholar
• HARDY DJ, GUAY DR, JONES RN: Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological and clinical overview. Diagn Microbial Infect. Dis. (1992) 15:39–53.
   PubMed Web of Science ®Google Scholar
• FERRERO JL, BOPP BA, MARSH KC, QUIGLEY SC, JOHNSON MJ, ANDERSON DJ et al.: Metabolism and disposition of clarithromycin in man. Drug Metall Dispos. (1990) 18:441–446.
   PubMed Web of Science ®Google Scholar
• CHU SY, GRANNEMAN GR,
   Google Scholar
• PICHOTTA PJ, DECOURT JP, GIRAULT J, FOURTILLAN JB: Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. j Clin. Pharmacal (1993) 33:480–485.
   Google Scholar
• GUAY DRP: Pharmacokinetics of new macrolides. Infect. Med. (1992) 9(Suppl.A):31–38.
   Google Scholar
• HOPKINS S: Clinical toleration and safety of azithromycin in adults and children. Rev. Contemp. Pharmacother. (1994) 5:383–389.
   Google Scholar
• ALVAREZ-ELCORO S, ENZLER MJ: The macrolides: erythromycin, clarithromycin and azithromycin. Mayo. Cilia. Proc. (1999) 74:613–634.
   PubMed Web of Science ®Google Scholar
• GUAY DR, PATTERSON DR, SEIPMAN N, CRAFT JC: Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Sal: (1993) 8:350–364.
   PubMed Web of Science ®Google Scholar
• ANDERSON G, ESMONDE TS, COLES S, MACKLIN J, CARNEGIE C: A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. Antimicrob Cliemother. (1991) 27(SuppLA):117–124.
   Google Scholar
• WALLACE RJ Jr, BROWN BA, GRIFFITH DE: Drug intolerance to high-dose clarithromycin among elderly patients. Diagn. Nlicrobial Infect. Dis. (1993) 16:215–221.
   PubMed Web of Science ®Google Scholar
• YEW WW, CHAU CH, LEE J, LEUNG CW: Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection (letter). Cilia. Infect. Dis. (1994) 18:1025–1026.
   PubMed Web of Science ®Google Scholar
• SHAHEEN N, GRIMM IS: Fulminant hepatic failure associated with clarithromycin. Am. j Castroenteral (1996) 91:394–395.
   PubMed Web of Science ®Google Scholar
• LIVIU L, YAIR L, YEHUDA S: Pancreatitisinduced by clarithromycin (letter). Ann. Intern. Med. (1996) 125:701.
   PubMed Web of Science ®Google Scholar
• PIJPERS E, VAN RIJSWIJK RE, TAKX-KOHLEN B, SCHREY G: A clarithromycin-induced myasthenic syndrome. Cilia. Infect. Dis. (1996) 22:175–176.
   PubMed Web of Science ®Google Scholar
• PERITI P, MAZZEI T, MINI E, NOVELLI A: Pharmacokinetic drug interactions of macrolides. Cilia. Pharmacakinet. (1992) 23:106–131.
   PubMed Web of Science ®Google Scholar
• WATKINS VS, POLK RE, STOTKA JL: Drug interactions of macrolides: emphasis on dirithromycin. Ann. Pharmacother. (1997) 31:349–356.
   PubMed Web of Science ®Google Scholar
• LUDDEN TM: Pharmacokinetic interactions of the macrolide antibiotics. Cilia. Pharmacakinet. (1985) 10:63–79.
   PubMed Web of Science ®Google Scholar
• NAWARSKAS JJ, McCARTHY DM, SPINLER SA: Digoxin toxicity secondary to clarithromycin therapy. Ann. Pharmacother. (1997) 31:864–866.
   PubMed Web of Science ®Google Scholar
• SPICER ST, LIDDLE C, CHAPMAN JR, BARCLAY P, NANKIVELL BJ, THOMAS P et al.: The mechanism of cyclosporine toxicity induced by clarithromycin. Br I
   Google Scholar
• Pharmacal (1997) 43:194–196.
   Google Scholar
• BROWN BA, WALLACE RJ Jr, GRIFFITH DE, WARDEN R: Clarithromycin-associated digoxin toxicity in the elderly. Clic]. Infect. Dis. (1997) 24:92–93.
   PubMed Web of Science ®Google Scholar
• PAAR D, TERJUNG B, SAUERBRUCH T: Life-threatening interaction between clarithromycin and disopyramide (letter). Lancet (1997) 349:326–327.
   PubMed Web of Science ®Google Scholar
• GRAU E, REAL E, PASTER E: Interaction between clarithromycin and oral anticoagulants (letter). Ann. Pharmacother. (1996) 30:1495–1496.
   PubMed Web of Science ®Google Scholar
• GILLUM JG, ISRAEL DS, SCOTT RB, CLIMO MW, POLK RE: Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrob. Agents Chemothera. (1996) 40:1715–1716.
   PubMed Web of Science ®Google Scholar
• BEDFORD TA, ROWBOTHAM DJ: Cisapride: drug interactions of clinical significance. Drug Sal: (1996) 15:167–175.
   PubMed Web of Science ®Google Scholar
• YEATES RA, LAUFEN H,
   Google Scholar
• ZIMMERMANN T: Interaction between midazolam and clarithromycin: comparison with azithromycin. Int. I Cilia. Pharmacal Ther. (1996) 34:400–405.
   PubMed Web of Science ®Google Scholar
• SKETRIS IS, LIDDLE C, CHAPMAN JR,BARCLAY P, NANKIVELL BJ, THOMAS P et al.: Possible role of intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. Pharmacotherapy (1996) 16:301–305.
   Google Scholar
• VANCE E,WATSON-BITAR M, GUSTAVSON L, KAZANJIAN P: Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob. Agents Chemother. (1995) 39:1355–1360.
   PubMed Web of Science ®Google Scholar
• GUSTAVSON LE, CHU SY,
   Google Scholar
• MACKENTHUM A, GUPTA SD, CRAFT JC: Drug interaction between clarithromycin and oral zidovudine in HIV-1 infected patients (abstract). Cilia. Pharmacal Ther. (1993) 53:163.
   Web of Science ®Google Scholar
• VANCE E, GUZMAN J, BITAR M, KAZANJIAN P: Clarithromycin and zidovudine pharmacokinetic study (abstract).
   Google Scholar
• Int. Calif AIDS (1994) 10:201.
   Web of Science ®Google Scholar
• POLIS MA, PISCITELLI SC, VOGEL S, WITEBSKY FG, CON VILLE PS, PETTY B et al.: Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob. Agents Chemother. (1997) 41:1709–1714.
   PubMed Web of Science ®Google Scholar
• GILLUM JG, BRUZZESE VL, ISRAEL DS, KAPLOWITZ LG, POLK RE: Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Clin. Infect. Dis. (1996) 22:716–718.
   PubMed Web of Science ®Google Scholar
• McLINN, WILLIAMS: Incidence of antibiotic resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. Red Infect. Dis. J. (1996) Suppl.:S3–S9.
   Google Scholar
• FERWERDA et al.: J. Antimicrob. Chemother. (2001) 47:441–446.
   Web of Science ®Google Scholar
• AMERICAN THORACIC SOCIETY: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am. Rev. Respit: Dis. (1993) 148:1418–1426.
   PubMed Web of Science ®Google Scholar
• FANG G-D, FINE M, ORLOFF J et A: New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases Medicine (1990) 69:307–316.
   Google Scholar
• BARTLETT JG: Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semirr. Respir. Infect. (1997) 12:329–333.
   PubMedGoogle Scholar
• VERGIS EN, YU VL: Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Semirr. Respir: Infect. (1997) 12:322–328.
   PubMedGoogle Scholar
• DARK D: Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am. J. Med. (1991) 91(Supp13A):315–355.
   Google Scholar
• STAHL JE, BARZA M, DESJARDIN J, MARTIN R, ECKMAN MH: Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. (1999) 159:2576–2580.
   PubMed Web of Science ®Google Scholar
• GLEASON PP, MEEHAN TP, FINE JM, GALUSHA DH, FINE MJ: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. (1999) 159:2562–2572.
   Google Scholar
• LUBIN JH: Analysis under Cox's failure time model using weighted least squares. Biometrics (1980) 36(2):307–312.
   PubMed Web of Science ®Google Scholar
• PRENTICE RL, KALBFLEISCH JD: Hazard rate models with covariates. Biometrics (1979) 35(1):25–39.
   PubMed Web of Science ®Google Scholar
• MARSTON BJ, PLOUFFE JF, FILE TM, THE COMMUNITY-BASED PNEUMONIA INCIDENCE STUDY GROUP et al.: Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch. Intern. Med. (1997) 157:1709–1718.
   Google Scholar
• STEPHENSON J: Studies suggest a darker side of "benign" microbes. JAMA (1997) 38:1873–1878.
   Google Scholar
• TAYLOR-ROBINSON D: Infections due tospecies of Mycoplasma and Ureaplasma: an update. Clin. Infect. Dis. (1996) 23:671–684.
   PubMed Web of Science ®Google Scholar
• HAMMERSCHLAG MR: Antimicrobial susceptibility and therapy of infections caused by Chlamydia prreumorriae. Antimicrob. Agents Chemother. (1994) 38:1873–1878.
   PubMed Web of Science ®Google Scholar
• TROY CJ, PEELING RW, ELLIS AG et al.:Chlamydia prreumoniae as a new source of infectious outbreaks in nursing homes (published correction appears in JAMA, 1997; 278:118). JAMA (1997) 277:1214–1218.
   PubMed Web of Science ®Google Scholar
• BARTLETT JG, BREIMAN RF,
   Google Scholar
• MANDELL LA et al.: Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. (1998) 26:811.
   PubMed Web of Science ®Google Scholar
• BARTLETT JG, DOWELL SF, MANDELL LA, FILE TM Jr., MUSHER DM, FINE MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. (2000) 31:347–382.
   PubMed Web of Science ®Google Scholar
• MANDELL LA, MARRIE TJ,
   Google Scholar
• GROSSMAN RF, CHOW AW, HYLAND RH, THE CANADIAN COMMUNITY-ACQUIRED PNEUMONIA WORKING GROUP: Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Chia. Infect. Dis. (2000) 31:383–421.
   PubMedGoogle Scholar
• ANZUETO A, NIEDERMAN MS, TILLOTSON GS, BRONCHITIS STUDY GROUP: Etiology, susceptibility and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg bid versus clarithromycin 500 mg bid. Clin. Therapeu. (1998) 20:885–890.
   Google Scholar
• CHODESH S, SCHREURS A, SIAMI G, BARKMAN JR. HW, ANZUETO A, SHAN M, MOESKER H, STACK T, KOWALSKY S, BRONCHITIS STUDY GROUP: Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. (1998) 27:730–738.
   PubMed Web of Science ®Google Scholar
• HOOTEN TM: A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am. J. Med. (1991) 91(Suppl.A):23–26.
   Google Scholar
• LEVENSTEIN JH: Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis. J. Antimicrob. Chemother. (1991) 27(Suppl.A):67–74.
   Google Scholar
• BACHAND RT: A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. J. Antmicrob. Chemother. (1991) 27(Suppl.A):75–82.
   Google Scholar
• CENTER FOR DISEASE CONTROL AND PREVENTION: 1997 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR (1997) 46:1–46.
   PubMedGoogle Scholar
• COLES SJ. ADDLESTONE MB, KAMDAR MK et al.: A comparative study of clarithromycin and amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Infection (1993) 21:272–278.
   Google Scholar
• MALLORY SB: Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. Am. J. Med. (1991) 91\(Supp1.3A):36S–39S.
   Google Scholar
• PARISH LC: Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int. J. Dermatol (1993) 32:528–532.
   PubMed Web of Science ®Google Scholar
• MARTIN DH, MROCZKOWSKI TF, DALU ZA et al.: A controlled trial of a single dose of azithromycin for the treatment of Chlamydial urethritis and cervicitis. N Eng. J. Med. (1992) 327:921–925.
   PubMed Web of Science ®Google Scholar
• PETERSON, GRAHAM DY, MARSHALL B et al.: Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized double-blind trial. Am. J. Castroenterol (1994) 88:1860–1864.
   Web of Science ®Google Scholar
• McNULTY CA, DENT JC: Susceptibility of clinical isolates of Campylobacter pylorito twenty-one antimicrobial agents. Eur. I an.
   Google Scholar
• Microbiol. Infect. Dis. (1988) 7:566–569.
   Google Scholar
• HULTEN K, CARS 0, HJELM E, ENGSTRAND L: In vitro activity of azithromycin against intracellular Helicobacter pylori j Antimicrob. Chemother. (1996) 37:483–489.
   Web of Science ®Google Scholar
• HARRISON JD, JONES JA, MORRIS DL: Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur. j Clin. Microbial. Infect. Dis. (1991) 10:862–84.
   PubMed Web of Science ®Google Scholar
• BERTONI G, SASSATELLI R, NIGRISOLI E, TANSINIP, BIANCHI G, DELLA CASA G et al.: Triple therapy with azithromycin, omeprazole and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am. j Castratenteral (1996) 91:258–263.
   Google Scholar
• AL-ASSI MT, GENTA RM, KARTTUNEN TJ, COLE RA, GRAHAM DY: Azithromycin triple therapy for Helicobacter pylon infection: azithromycin, tetracycline and bismuth. Am. j Castroenteral (1995) 90:403–405.
   PubMed Web of Science ®Google Scholar
• TURSI A, CAMMAROTA G, MONTALTO M, PAPA A, FEDELI G, GASBARRINI G: The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection (letter). Am. Castroenteral. (1996) 91:817–818.
   PubMed Web of Science ®Google Scholar
• PILOTTO A, DIMARIO F, FRANCESCHI
   Google Scholar
• M, LEANDRO G, SOFFIATI G, SCAGNELLI M et al.: Cure of Helicobacter pylon infection in the elderly: effects of eradication on gastritis and serological markers. Aliment. Pharmacal Titer. (1996) 10:1021–1027.
   PubMed Web of Science ®Google Scholar
• CASELLI M, RUINA M, FABBRI E BALHOUS W, ALVISI V: A comparative trial of short term therapy with omeprazole plus either amoxycillin or azithromycin for Helicobacter pylori eradication (letter). Antimicrob. Chemother. (1996) 37:849–850.
   Web of Science ®Google Scholar
• CASELLI M, TREVISANI L, TURSI A, SARTORI S, RULNA M, LUZZI I et al.: Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori Eur. Castroenteral. Hepatal. (1997) 9:45–48.
   PubMed Web of Science ®Google Scholar
• WALLACE RJ, BROWN BA, GRIFFITH DE etal.: Initial clarithromycin monotherapy for Mycobacterium-avium-intracellulare complex lung disease. Am. I Respir: Grit. Care Med. (1994) 149:1335–1341.
   Google Scholar
• DAUTZENBERG B, SAINT MARC T, MEYOHAS MC et al.:Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch. Intern. Med. (1993) 153:368–372.
   Google Scholar
• HUSSON RN, ROSS LA, SANDELL S et al.: Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immuinodeficiency syndrome. Pediatr. (1994) 125:807–814.
   Web of Science ®Google Scholar
• NAIK S, RUCK R: In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob. Agents Chemother. (1989) 33:1614–1616.
   PubMed Web of Science ®Google Scholar
• BROWN ST, EDWARDS FF, BARNARD EM, TONG W, ARMSTRONG D: Azithromycin, rifabutin and rifapentine for treatment of prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. Antimicrob. Agents Chemother. (1993) 37:398–402.
   PubMed Web of Science ®Google Scholar
• BERRY A, KOLETAR S, WILLIAMS DJ: Azithromycin therapy for disseminated Mycobacterium avium intracellular in AIDS patients. Programme and Abstracts of the Pt National Conference on Human Retro viruses and Related Infections, National Foundation for Infectious Diseases and the American Society for Microbiology. Washington, DC, December 12–16, 1993:106.
   Google Scholar
• PIERCE M, CRAMPTON S, HENRY D et al.: A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients wth advanced acquired immunodeficiency syndrome. N Engl. Med. (1996) 335:384–391.
   PubMed Web of Science ®Google Scholar
• DEVER LL, JORGENSEN JH, BARB OUR AG: Comparative in vitro activities of clarithromycin, azithromycin and erythromycin against Borrelia burgdorkfi. Antimicrob. Agents Chemother. (1993) 37:1704–1706.
   PubMed Web of Science ®Google Scholar
• PREAC-MURSIC V, WILSKE B, SCHIERZ G, SUSS E, GROSS B: Comparative antimicrobial actvity of the new macrolides against Borrelia burgdorkri Eur. Clin. Microbial Infect. Dis. (1989) 8:651–653.
   PubMed Web of Science ®Google Scholar
• JOHNSON RC, KODNER C, RUSSELL M, GIRARD D: In vitro and in vivo susceptibility of Borrelia burgdorkfi to azithromycin. I Antimicrob. Chemother. (1990) 25(Suppl.A):33–38.
   Google Scholar
• MASSAROTTI EM, LUGER SW, RAHN DW, MESSNER EP, WONG JB, JOHNSON RC: Treatment of early Lyme disease. Am. I Med. (1992) 92:396–403.
   Google Scholar
• STRIE F, RUZIC E, CIMPERMAN J: Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethyl-penicillin. I Antimicrob. Chemother. (1992) 30:543–550.
   PubMed Web of Science ®Google Scholar
• WEBER K, WILSKE B, PREAC-MURSIC V, THURMAYR R: Azithromycin versus penicillin V for t he treatment of early Lyme borreliosis. Infection (1993) 21:367–372.
   Google Scholar
• LUFT BJ, DATTWYLER RJ, JOHNSON RC, LUGER SW, BOSIER EM, RAHN DW et al.: Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann. Intern. Med. (1996) 124:785–791.
   PubMed Web of Science ®Google Scholar
• STRIE E MARASPIN V, LOTRIC-FURLAN S, RUZIC-SABIJIC E, CIMPERMAN J: Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection (1996) 24:64–68.
   PubMed Web of Science ®Google Scholar
• CANTIN L, CHAMBERLAND S: In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Taxoplasma gandii Antimicrob. Agents Chemother. (1993) 37:1993–1996.
   PubMed Web of Science ®Google Scholar
• HARDY WD, BOZZETTE S, SAFRIN Set al.: Results from recent therapeutic trials for opportunistic infections from the United States. AIDS (1994) 8:S15.
   Google Scholar
• GUERRA LG, NEIRA CJ, BOMAN D, HO H, CASNER PR, ZUCKERMAN Met al.: Rapid response of AIDS-related bacillary angiomatosis to azithromycin. Clin. Infect. Dis. (1993) 17:264–266.
   Google Scholar
• CHIA JK, NAKATA MM, LAMI JL, PARK SS, DING JC: Azithromycin for the treatment of cat-scratch disease. Clin. Infect. Dis. (1998) 26:193–194.
   PubMed Web of Science ®Google Scholar
• HOQUE S, WEIR A, FLUCK R, CUNNINGHAM J: Rhodococcus egui in CAPD-associated peritonitis treated with azithromycin. Nephrol. Dial. Transplant. (1996) 11:2340–2341.
   PubMed Web of Science ®Google Scholar
• MASCELLINO MT, IONOA E, PONZO R, MASTROIANNI CM, DELIA S: Infections due to Rhadocaccus equi in three HIV-infected patients: microbiological findings and antibiotic susceptibility. Int.
   Google Scholar
• Pharmcal Res. (1994) 14:157–163.
   Google Scholar
• HICKS P, ZWIENER RJ, SQUIRES J, SAVELLV: Azithromycin therapy for Cryptosporidium parvurn infection in four children infected with human immunodeficiency virus. I Pediatr. (1996) 129:297–300.
   Google Scholar
• BLANSHARD C, SHANSON DC, GAZZARD BG: Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Int. STD AIDS (1997) 8:124–129.
   PubMed Web of Science ®Google Scholar
• BARZA M, EISENBERG E: Clarithromycin and azithromycin. Infect. Dis. art Pict. (1996) 5:291–302.
   Web of Science ®Google Scholar
• LACASSIN F, SCHAFFO D, PERRONNE
   Google Scholar
• C, LONGUET P, LEPORT C, VILDE JL: Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus (letter). Aritimicrob. Agents Chemother. (1995) 39:276–277.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-MARTIN J, LEPORT C, MORIAT P, MEYOHAS MC, CHAUVIN JP, VILDE JL: Pyrimethamine-clarithromycin combination for therapy of acute Taxoplasma encephalitis in patients with AIDS. Antimicrob. Agents Chernother. (1991) 35:2049–2052.
   PubMed Web of Science ®Google Scholar
• RAFFI F, STRUILLOU L, NININ E, RELIQUET V, BILLAUD E, MLPIED B: Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin (letter). OM. Infect. Dis. (1995) 20:1076–1077.
   Web of Science ®Google Scholar
• BASS JW, VINCENT JM, PERSON DA: The expanding spectrum of Bartoriella infections. II: Cat-scratch disease. PedMtr. Infect. Dis. J. (1997) 16:163–179.
   PubMed Web of Science ®Google Scholar
• DATTWYLER RJ, GRUNWALDT E, LUFT BJ: Clarithromycin in treatment of early Lyme disease: a pilot study. Aritimicrob. Agents Chemotherp. (1996) 40:468–469.
   PubMed Web of Science ®Google Scholar
• GIRGIS NI, FRENCK RW, SULTAN Y: Single dose azithromycin compared to a four dose rifampin regimen for the eradication of meningococcal nasopharyngeal carriage (abstract). Program Abstr. Iritersci. Corif Aritimicrob. Agents Chemother. (1997) 37:364.
   Google Scholar
• ANDERSEN SL, AGER A, McGREEVY P, SCHUSTER BG, WESCHE D, KUSCHNER R et al.: Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am. Trap. Med. Hyg. (1995) 52:159–161.
   PubMed Web of Science ®Google Scholar
• GINGRAS BA, JENSEN JB: Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am. j Trap. Med. Hyg. (1992) 47:378–382.
   Google Scholar
• DAJANI AS, TAUBERT KA, WILSON W,
   Google Scholar
• BOLGER AF, BAYER A, FERRIERIP et al.: Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA (1997) 277:1794–1801.
   PubMed Web of Science ®Google Scholar
• ROUSE MS, STECKELBERG JM, BRANDT CM, PATEL R, MIRO JM, WILSON WR: Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Aritimicrob. Agents Chemother. (1997) 41:1673–1676.
   PubMed Web of Science ®Google Scholar
• WARD TT, RIMLAND D, KAUFFMAN
   Google Scholar
• C, HUYCKE M, EVANS TG, HEIFETS L: Randomized, oepn-label trial of azithromycin plus ethambutol vs clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. OM. Infect. Dis. (1998) 27:1278–1285.
   Web of Science ®Google Scholar
• MUHLESTEIN JB, ANDERSON JL, CARLQUIST JF et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Circulation (2000) 102:1755–1760.
   PubMed Web of Science ®Google Scholar
• DESTACHE CJ, DEWAN N, O'DONOHUE WJ, CAMPBELL JC, ANGELILLO VA: Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. Aritimicrob. Chemother. (1999) 43(Suppl.A):107–113.
   Google Scholar
• HARNETT, J, WILSON J. Effectiveness of azithromycin (AZ) in patients withcommunity-acquired pneumonia (CAP): an evidenced-based meta-analysis ofrandomized controlled trials. 11th Annual Meeting, European RespiratorySociety, Berlin, Germany (September 22–26, 2001). Abstract: P923.
   Google Scholar
• BARRY AL, FUCHS PC, BROWN SD: Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from outpatients in the USA. Aritimicrob. Chemother. (1997) 40:139–140.
   PubMed Web of Science ®Google Scholar
• LEFEVRE JC, ESCAFFRE MC, COURDIL
   Google Scholar
• M, LARENG MB: In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. Pathal Biol. (Paris) (1993) 41:313–315.
   PubMed Web of Science ®Google Scholar
• THOMSON KS, CHARTRAND SA, SANDERS CC, BLOCK SL: Trovatioxacin, a new fluoroquinolone with potent activity against Streptococcus prieumardae. Aritimicrob. Agents Chemother. (1997) 41:478–480.
   PubMed Web of Science ®Google Scholar
• GORDILLO ME, SINGH KV, MURRAY BE: In vitro activity of azithromycin against bacterial enteric pathogens. Aritimicrob. Agents Chemother. (1993) 37:1203–1205.
   PubMed Web of Science ®Google Scholar
• FASS RJ: Erythromycin, clarithromycin and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Aritimicrob. Agents Chemother. (1993) 37:2080–2086.
   PubMed Web of Science ®Google Scholar
• BLONDEAU JM: A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. j Aritimicrob. Chemother. (1999) 43(suppl. B):1–11.
   Google Scholar
• DELMEE M, CARPENTIER M, GLUPCZYNSKI Y et al: In vitro susceptibilities of 180 clinical isolates of Haemaphilus irilluerizae to ampicillin, amoxycilliniclavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin and azithromycin. Acta OM. Belg. (1996) 51:237–243.
   PubMed Web of Science ®Google Scholar
• NEU HC, CHIN NX, SAHA G, LABTHAVIKUL P: Comparative in vitro activity oe the new oral macrolide azithromycin. Eur. j OM. Microbial Infect. Dis. (1998) 7:541–544.
   Web of Science ®Google Scholar
• BARRY AL, JONES RN, THORNBERRY C: In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin and clindamycin. Aritimicrob. Agents Chemother. (1988) 32:752–754.
   PubMed Web of Science ®Google Scholar
• RENAUDIN H, BEBEAR C: Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma prieumoniae, Mycoplasma &minis and Lfreaplasma urealyticum. Eur. Microbial Infect. Dis. (1990) 9:838–841.
   PubMed Web of Science ®Google Scholar
• ISHIDA K, KAKU M, IRIFUNE K et al: In vitro and in vivo activities of macrolides against Mycoplasma prieumardae. Aritimicrob. Agents Chemother. (1994) 38:790–798.
   PubMed Web of Science ®Google Scholar
• BARRY AL, FUCHS PC, BROWN SD: Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics (letter). Aritimicrob. Chemother. (1995) 35:552–555.
   PubMed Web of Science ®Google Scholar
• VAN ASSELT GJ, SLOOS JH, MOUTON RE VAN BOVEN CP, VAN DE KLUNDERT JA: Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. j Med. Microbial (1995) 43:386–391.
   PubMed Web of Science ®Google Scholar
• WELSH L, GAYDOS C, QUINN TC: In vitro activities of azithromycin, clarithromycin, erythromycin and tetracycline against 13 strains of Chlamydia prieumoniae. Aritimicrob. Agents Chemother. (1996) 40:212–214.
   Google Scholar
• KINASEWITZ G, WOOD RG:
   Google Scholar
• Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur.j. Microbial. Infect. Dis. (1991) 10:872–877.
   PubMed Web of Science ®Google Scholar
• SCHONWALD S, SKERK V,
   Google Scholar
• PETRICEVIC I etal.: Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur. I OM. Microbial (1991) 11:877–880.
   Google Scholar
• RAMIREZ J, UNOWSKY J, TALBOT GH et al.: Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. OM. Ther. (1999) 21:103–117.
   Google Scholar
• PATEL T, DESAI R, DUFF J et al.: Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia. In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 37th Annual Meeting. Washington, DC: American Society for Microbiology (1997).
   Google Scholar
• SULLIVAN J, GEZON D, HOPKINS W: A double-blind, randomized, multicenter study in ambulatory community-acquired pneumonia comparing trovafloxacin with clarithromycin. In: Abstracts of the Interscience Conference On Antimicrobial Agents and Chemotherapy 37th Annual Meeting, Washington, DC: American Society for Microbiology (1997).
   Google Scholar
• CHIEN SM, PICHOTTA P, SIEPMAN N, CANADA-SWEDEN CLARITHROMYCIN PNEUMONIA STUDY GROUP et al.: Treatment of community-acquired pneumonia: a multicenter, double-blind randomized study comparing clarithromycin with erythromycin. Chest (1993) 103:697–701.
   Google Scholar
• NEU HC, CHICK TW: Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest (1993) 104:1393–1399.
   PubMed Web of Science ®Google Scholar
• BALMES P, CLERC G, DUPONT B etal.: Comparative study of azithromycin and amoxicillinklavulanic acid in the treatment of lower respiratory tract infections. Eur. I OM. Microbial Infect. Dis. (1991) 10:437–439.
   Google Scholar
• SCHONWALD S, GUNJACA M, KOLACNY-BABIC L et al.: Comparison of azithromycin and erythromycin in the treatment of atypical pneumonia. Antimicrob. Chemother. (1990) 25(SuppLA):123–126.
   Google Scholar
• GENNE D, SIEGRIST HH, HUMAIR L et al.: Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur. I OM. Microbial Infect. Dis. (1997) 16:783–788.
   Google Scholar
• BOHTE R, VAN'TWOUT JW, LOBATTO S et al.: Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur. I OM. Microbial Infect. Dis. (1995) 14:182–187.
   PubMedGoogle Scholar
• LODE H, GARAUJ, GRASSI C etal.: Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur. Respir J. (1995) 8:1999–2007.
   Google Scholar
• MOOLA S, HAGBERG L,
   Google Scholar
• CHURCHYARD A et al.: Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia (CAP) (abstract L-113). In:
   Google Scholar
• Program arid Abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy Washington, DC: American Society for Microbiology (1997).
   Google Scholar
• FOGARTY C, GROSSMAN C, WILLIAMS J et al.: Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect. Med. (1999) 16:748–763.
   Web of Science ®Google Scholar
• O'DOHERTY B, MULLER 0: Randomized, multicenter study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia - Azithromycin Study Group. Eur.j. OM. Microbial Infect. Dis. (1998) 17:828–833.
   PubMed Web of Science ®Google Scholar
• BRADBURY F: Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. _J. Aritimicrob. Chemother. (1993) 31 (Suppl.E):153–162.
   Google Scholar
• JANG TN, LIU CY, WANG FD, YANG SP, FUNG CP: A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia. Chin. Med. j( Engfi (1995) 55:302–306.
   Google Scholar
• RIZZATO G, MONTEMURRO L, FRAIOLL P et al.: Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur. Respir: 1 (1995) 8:398-402.
   Google Scholar
• VERGIS EN, INDORF A, FILET etal.: Azithromycin vs cefuroxime pllus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch. Intern. Med 160:1294–1300.
   Google Scholar
• PLOUFFE J, SCHWARTZ DB, KOLOKATHIS A, THE AZITHROMYCIN INTRAVENOUS CLINICAL TRIALS GROUP et al: Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Aritimicrob. Agents Chemother. (2000) 44:1796–1802.
   PubMed Web of Science ®Google Scholar
• UZUN 0, HAYRAN M, AKOVA M, GUR D, AKALIN HE: Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. j. Chemother. (1994) 6:53–57.
   Google Scholar
• BOCCAZZI A, TONELLI P, DE'ANGELIS M et al: Short course therapy with ceftibuten versus azithromycin in pediatric streptococcal pharyngitis. Pediatr. Infect. Dis. 1 (2000) 19:963-967.
   Google Scholar
• STILL JG, HUBBARD WC, POOLE JM et al.: Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibibiotic therapies. Ped. Infect. Dis. I (1993) 12\(Supp1.3):5134–5141.
   Google Scholar
• SCHAAD UB, HEYNEN G: Evaluation of the efficacy, safety and toleration of azithromycin vs penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. Pediatr Infect. Dis. J. (1996) 15:791–795.
   PubMed Web of Science ®Google Scholar
• McCARTY J, HEDRICK JA, GOOCH WM: Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv. Ther. (2000) 17:14–26.
   PubMed Web of Science ®Google Scholar
• PACIFICO L, SCOPETTI F, RANUCCI A, PATARACCHIA M, SAVIGNONI F, CHIESA C: Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Aritmicrob. Agents Chemother. (1996) 40:1005–1008.
   Google Scholar
• STILL JG: Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: treatment options. Pediatr. Infect. Dis. J. (1995) 14 (Suppl.):S57–561.
   Google Scholar
• POZZI E, GROSSI E, PECORI A, THE AZITHROMYCIN RESEARCH GROUP: Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Cur Therapeu. Res. (1994) 55(7):759–764 zoo. MERTENS JCC, VAN BARNEVELD PWC, ASIN HRG et al: Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. (1992) 36:1456–1459.
   Google Scholar
• ANZUETO A, NIEDERMAN MS, HAVERSTOCK DC, TILLOTSON GS: Efficacy of ciprofloxacin in acute bacterial exacerbations of complicated chronic bronchitis: Interim analysis. Chic Therapeut. (1997) 19(5):1–13.
   Google Scholar
• WETTENGEL R, VETTER N, WAARDENBURG FA: Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis. Antimicrob. Chemother. (1993) 31:963–972.
   Google Scholar
• BACHAND RT: Comparative study of clarithromycin and ampicillin in the treatment of patients with acute exacerbations of chronic bronchitis. _J. Antimicrob. Chen/other. (1991) 27(Suppl.A):91–100.
   Google Scholar
• ADAM D: Clarithromycin 250 mg b.i.d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis. Infection (1993) 21:265–271.
   Google Scholar
• BIEBUYCK XA, AZITHROMYCIN STUDY GROUP: Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. j Int. Med. (1996) 24:407–418.
   Google Scholar
• CALHOUN KH, HOKANSON JA: Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Arch. Fam. Med. (1993) 2:837–840.
   PubMedGoogle Scholar
• DUBOIS J, SAINT-PIERRE C, TREMLAY
   Google Scholar
• C: Efficacy of clarithromycin vs amoxicillin/ clavulanate in the treatment of acute maxillary sinusitis. Ear Nose, Throat (1993) 72:804–810.
   PubMedGoogle Scholar
• KARMA P, PUKANDER J, PENTTILA M etal.: The comparative efficacy and safety of clarithromycin and amoxicillin in the treatment of outpatients with acute maxillary sinusitis. j Antimicrob. Chemother. (1991) 27(Suppl.A):83–90.
   Google Scholar
• CASIANO RR: Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am. j Med. (1991) 91(Suppl.A):83–90.
   Google Scholar
• CLEMENT PA, deGANDT JB: A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxclav in the treatment of sinusitis in adults.
   Google Scholar
• Med. Res. (1998) 26:66–75.
   Google Scholar
• DANIEL RR: Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. j Antimicrob. Chemother. (1993) 31(suppl. E):65–71.
   Google Scholar
• GOOCH WM, GAN VN, CORDER WT etal.: Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children. Pediatr. Infect. Dis. (1993) 12\(Supp1.3):5128–5133.
   Google Scholar
• McCARTY JM„PHILLIPS A, WIISANEN R: Comparative safety and efficacy of clarithromycin in the treatment of acute otitis media in children. Pediatr. Infect. Dis. J. (1993) 12\(Supp1.3):5122–5127.
   Google Scholar
• COLES SJ, ADDLESTONE MB, KAMDAR MK et al.: A Comparative study of clarithromycin and amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Infection (1993) 21:272–278.
   PubMed Web of Science ®Google Scholar
• DAGAN R, JOHNSON CE, McLINN S et al: Bacteriologic and clinical efficacy of amoxicilliniclavulanate vs azithromycin in acute otitis media. Pediatr Infect. Dis. (2000) 19:95–104.
   Google Scholar
• PUKANDER JS, FERO JP, KAPRIO EA, SORRI MJ: Clarithromycin vs amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. PedMti: Infect. Dis. J. (1993) 12 (Supp1.3):5118–S121.
   Google Scholar
• ASPIN MM, HOBERMAN A, McCARTY J etal.: Comparative study of the safety and
   Google Scholar
• efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. j Pediatr. (1994) 125:136–141.
   Google Scholar
• PRINCIPI N: Multicenter comparative study of the efficacy and safety of azithromycin compared with amoxicillin/ clavulanic acid in the treatment of paediatric patients with otitis media. Eur. j Chic Microbial. Infect. Dis. (1995) 14:669–676.
   PubMed Web of Science ®Google Scholar
• LASSUS A: Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. Antimicrob. Chemother. (1990) 25(Suppl.):115–121.
   Google Scholar
• KIANI R: Double-blind, double-dummy comparison of azithromycin and cephalexin in treatment of skin and skin structure infections. Eur. j CM]. Microbial. Infect. Dis. (1991) 10:880–884.
   PubMed Web of Science ®Google Scholar
• JOHNSON RB: The role of azalide antibiotics n the treatment of Chlamydia. Am. J. Obstet. Cyriecol. (1991) 64:1794–1796.
   Web of Science ®Google Scholar
• STEINGRIMSSON 0, OLAFSSON JH, THORARINSSON H et al.: Azithromycin in the treatment of sexually transmitted disease. j Antimicrob. Chemother. (1990) 25 (Suppl.A) :109–114.
   Google Scholar